Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation er húðsjúkdómur sem einkennist af auknu litarefni í húðinni eftir bólgu í húðinni. Postinflammatory hyperpigmentation getur stafað af langvarandi sólarljósi, bólgu eða öðrum húðmeiðslum, þar með talið þeim sem tengjast unglingabólum. Fólk með dekkri húðlit er venjulega hættara við oflitarefni með of mikilli sólarljósi.
☆ Í niðurstöðum Stiftung Warentest 2022 frá Þýskalandi var ánægja neytenda með ModelDerm aðeins minni en með greiddum fjarlækningaráðgjöfum.
References
Postinflammatory hyperpigmentation (PIH) er algengt húðvandamál sem kemur fram eftir húðbólgu eða meiðsli. Það hefur tilhneigingu til að endast lengi og er verra hjá fólki með dekkri húðlit (Fitzpatrick skin types III–VI) . Þó það lagast oft af sjálfu sér getur þetta tekið smá tíma og því þarf oft meðferð í langan tíma. Að sameina mismunandi meðferðir virkar best.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation er algeng afleiðing húðbólgu. Það hefur tilhneigingu til að hafa alvarlegar og oftar áhrif á dökkhærða einstaklinga. Rannsóknir sýna að vandamál eins og postinflammatory hyperpigmentation eru meðal helstu ástæðna fyrir því að fólk með dekkri húðlit leitar eftir húðmeðferð. Snemma meðferð skiptir sköpum til að leysa postinflammatory hyperpigmentation og byrjar venjulega með því að stjórna upphaflegu bólguástandinu. Fyrsta meðferðarlínan felur venjulega í sér að nota staðbundin efni sem létta húðina ásamt sólarvörn til verndar. Þessi efni, eins og hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , geta í raun dregið úr of mikilli litarefni. Að auki eru retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy einnig notaðir sem litahreinsunarefni, með nýjum meðferðum. Þó staðbundnar meðferðir séu venjulega árangursríkar við oflitarefni á yfirborði, geta aðgerðir (laser, chemical peel) verið nauðsynlegar fyrir þrjósk tilfelli. Það er mikilvægt að gæta varúðar við þessar meðferðir til að forðast ertingu og versnun postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
